Thank you for your interest in the article entitled “New therapeutic agents in diabetic nephropathy” [1] and your comments on erroneous information therein. We agree that there are several errors in the article; therefore, we have made the following revisions according to your comments.
The ongoing ‘Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria’ (PRIORITY) trial is investigating the efficacy of the mineralocorticoid receptor antagonist (MRA) spironolactone, in terms of delaying the progression of early diabetic nephropathy (DN) [2]. However, concerns regarding the development of hyperkalemia in those with decreased renal function need to be addressed. The nonsteroidal MRA finerenone (BAY 94-8862) was well-tolerated in a Japanese population with DN and did not exert adverse effects on serum potassium levels or renal function [3,4]. A study of the safety of the selective aldosterone receptor antagonist MT-3995 regarding the development of hyperkalemia in subjects with DN is required [5].
We appreciate your interest in, and comments on, our article and we hope that our revisions have addressed your concerns.
Footnotes
No potential conflict of interest relevant to this article was reported.
REFERENCES
- 1.Kim Y, Park CW. New therapeutic agents in diabetic nephropathy. Korean J Intern Med. 2017;32:11–25. doi: 10.3904/kjim.2016.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Lindhardt M, Persson F, Currie G, et al. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. BMJ Open. 2016;6:e010310. doi: 10.1136/bmjopen-2015-010310. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Katayama S, Yamada D, Nakayama M, et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complications. 2017;31:758–765. doi: 10.1016/j.jdiacomp.2016.11.021. [DOI] [PubMed] [Google Scholar]
- 4.Sato N, Ajioka M, Yamada T, et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circ J. 2016;80:1113–1122. doi: 10.1253/circj.CJ-16-0122. [DOI] [PubMed] [Google Scholar]
- 5.Kolkhof P, Nowack C, Eitner F. Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015;24:417–424. doi: 10.1097/MNH.0000000000000147. [DOI] [PubMed] [Google Scholar]